Key Points Viking Therapeutics' shares plunged after mixed phase 2 results for a GLP-1 candidate. However, the data wasn't nearly as bad as the market's reaction suggested. Viking could soar on future progress with this and other candidates. 10 stocks we like better than Viking Therapeutics › Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize on the t ...